Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disoproxil fumarate

- PMLiVE

ViiV files two-drug HIV maintenance regimen

SWORD studies show treatment could maintain viral suppression

- PMLiVE

Gilead plans fightback against HIV arch-rival ViiV

Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

- PMLiVE

Gilead Sciences appoints general manager, Canada

Nordics general manager Kennet Brysting moves to take up new post

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

A healthy challenge

The EC’s Dr Vytenis Andriukaitis on Europe’s problems with health

- PMLiVE

Efficacy trials get underway for HIV vaccine in South Africa

Study hopes to provide partial immunity against the virus

- PMLiVE

Another late-stage setback tarnishes Gilead’s R&D lustre

Myelofibrosis drug candidate fails to best Incyte/Novartis’ Jakafi in phase III trials

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

- PMLiVE

Gilead chalks up trial success for new NASH drug

Phase II selonsertib data encouraging for liver disease with no approved therapies

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links